Naveen Pemmaraju, Professor in the Department of Leukemia at UT MD Anderson Cancer Center, shared a post on LinkedIn:
“Honored to have been invited to speak at American Society of Clinical Oncology (ASCO) 26 this year! We were able to highlight our growing BPDCN field with my own UT MD Anderson group’s novel investigator- initiated clinical trial as oral presentation “Tagraxofusp CD123-targeted + VEN + HCVAD” novel approach.
A wonderful, engaging MPN+BPDCN panel discussion led by Andrew Kuykendall.”
Other articles about ASCO2026 on OncoDaily.
